Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Asthma-II: Pathophysiology and Classification

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:

Asthma-IV: Diagnostic and Management

Asthma-IV: Diagnostic and Management

The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

Asthma-III: Symptoms and Complications

Asthma-III: Symptoms and Complications

Asthma, a common chronic respiratory condition, is classified considering the frequency and severity of symptoms alongside lung function impairment. Understanding this classification is essential for appropriate treatment and management. Here's a detailed look at the classification of asthma and its clinical features and complications:
Classification of Asthma

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Search research articles

Home
Dupilumab Efficacy By Disease Severity In Pediatric Type 2 Asthma.

Home
Dupilumab Efficacy By Disease Severity In Pediatric Type 2 Asthma.

Related Experiment Video

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dupilumab efficacy by disease severity in pediatric type 2 asthma.

Daniel J Jackson¹, Monika Gappa², Leonard B Bacharier³

¹University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin, USA.

Pediatric Allergy and Immunology : Official Publication of the European Society of Pediatric Allergy and Immunology

|November 7, 2025

View abstract on PubMed

Summary

This summary is machine-generated.

Long-term dupilumab treatment effectively reduced asthma exacerbations and improved lung function in children with moderate-to-severe type 2 asthma. These benefits were observed regardless of initial disease severity, indicating broad efficacy for this asthma biologic.

Keywords:

asthma clinical trial disease exacerbation dupilumab lung volumes patient‐reported outcome

More Related Videos

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Murine Model of Allergen Induced Asthma

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Related Experiment Videos

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Noninvasive Sampling of Mucosal Lining Fluid for the Quantification of In Vivo Upper Airway Immune-mediator Levels

Published on: August 7, 2017

Murine Model of Allergen Induced Asthma

Murine Model of Allergen Induced Asthma

Published on: May 14, 2012

Area of Science:

Pediatric Pulmonology
Immunology
Clinical Pharmacology

Background:

Dupilumab has shown efficacy in pediatric asthma patients.
This study is a post hoc analysis of the VOYAGE and EXCURSION trials.
The analysis focuses on long-term dupilumab efficacy based on asthma severity at baseline.

Purpose of the Study:

To assess the long-term efficacy of dupilumab in children with moderate-to-severe type 2 asthma.
To evaluate efficacy based on asthma severity (moderate vs. severe) at the start of the parent study.

Main Methods:

Children aged 6-11 years with moderate-to-severe type 2 asthma were included.
Participants received dupilumab every 2 weeks for an additional 52 weeks.
Outcomes measured included severe exacerbation rates, lung function (FEV1, FEV1 z-score), and asthma control (ACQ-7-IA).

Main Results:

Dupilumab significantly reduced annualized severe exacerbation rates in both moderate and severe asthma subgroups compared to placebo.
Sustained reductions in exacerbations were observed during the extension study.
Improvements in pre-bronchodilator percent predicted FEV1, FEV1 z-scores, and ACQ-7-IA scores were noted in both subgroups, with greater numerical improvements in severe asthma.

Conclusions:

Long-term dupilumab treatment improves lung function and asthma control in children with type 2 asthma.
Efficacy was observed irrespective of baseline disease severity.
Numerically greater improvements were seen in children with severe asthma.